Journal
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
Volume 33, Issue 3, Pages 707-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.idc.2019.05.004
Keywords
HIV-1; Treatment failure; Virologic failure; HIV drug resistance; Antiretroviral therapy
Categories
Funding
- National Institutes of Health [K23 A1143470, 5T32 A1007387, R01 A1124718, R01 A1098558]
- Harvard University Center for AIDS Research [P30 A1060354]
- Emory Center for AIDS Research [P30 A1050409]
- Massachusetts General Hospital Executive Committee on Research Fund for Medical Discovery
Ask authors/readers for more resources
Approximately 20% of people with HIV in the United States prescribed antiretroviral therapy are not virally suppressed. Thus, optimal management of virologic failure has a critical role in the ability to improve viral suppression rates to improve long-term health outcomes for those infected and to achieve epidemic control. This article discusses the causes of virologic failure, the use of resistance testing to guide management after failure, interpretation and relevance of HIV drug resistance patterns, considerations for selection of second-line and salvage therapies, and management of virologic failure in special populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
